Pharmacokinetic changes subsequent to renal failure;Modifications pharmacocinétiques au cours de I'insuffisance rénale

Presse Medicale

Volumn 30, Issue 12, 2001, Pages 597-604

  Launay Vacher, V ^a   Storme, T ^a   Izzedine, H ^a   Deray, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; KIDNEY FAILURE; KIDNEY METABOLISM; REVIEW;

GLOMERULAR FILTRATION RATE; KIDNEY; KIDNEY FAILURE; KIDNEY FAILURE, CHRONIC; LIVER; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RENAL DIALYSIS; TIME FACTORS;

EID: 0035978045     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Pharmacokinetics in patients with renal failure
2. Prediction of creatinin clearance from serum creatinine
3. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
4. Gastrointestinal parameters that influence oral medications
5. Kinetic analysis of D-xylose absorption in normal subjects and in patients with chronic renal failure
6. Pharmacocinétique et insuffisance rénale
7. Clinical pharmacokinetics of antibiotics in patients with impaired renal function
8. Drug protein binding in chronic renal failure: Evaluation of nine drugs
9. Disease-induced variations in plasma protein Levels. Implications for drug dosage regimens (Part I)
10. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II)
11. Investigation of the drug-binding defect in plasma from rats with glycerol-induced acute renal failure
12. Decreased drug binding in uraemia: Effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin
13. Interaction of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin
14. Pharmacokinetics of drugs and the effects of renal failure
15. Effect of renal failure on drug metabolism by the liver
16. Renal disease and drug metabolism: An overview
17. Consequences of renal insufficiency on the hepatic clearance of some drugs
18. Regulation of renal tubular secretion of organic compounds
19. Urinary excretion of drugs in chronic renal impairment with respect to changes their tubular handling by residual nephrons
20. Quantitative investigation of renal handling of drugs in dogs with renal insufficiency
21. Renal handling of drugs in renal failure. I: Differential effects of uranyl nitrate- and glycerol-induced acute renal failure on renal excretion of TEAB and PAH in rats
22. Drug metabolites in renal failure
23. Disposition of gabapentin in anuric subjects on hemodialysis
24. Determinants of drug removal by continuous hemofiltration
25. Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability
26. Drug dosage in patient during continuous renal replacement therapy
27. Pharmacokinetic studies in volunteers with renal impairment
28. Pharmacokinetics of diethylcarbamazine: Prediction by concentration in saliva
29. Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules
30. Pharmacokinetics of chloroquine: Saliva and plasma levels relationship
31. Therapeutic drug monitoring of once daily gentamicin in serum and saliva of children
32. Use of saliva specimens for monitoring indinavir therapy in human immunodeficiency virus-infected patients
33. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants
34. Saliva as a specimen for therapeutic drug monitoring in pharmacies